88 - References

References

92 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Heres S, et al. Pharmacokinetics of olanzapine long-­acting injection: the clinical perspective. Int Clin Psychopharmacol 2014; 29:299–312.
2. Mitchell M, et al. Single-­ and multiple-­dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-­acting injection: an open-­ label, multicenter, nonrandomized study in patients with schizophrenia. Clin Ther 2013; 35:1890–1908.
3. Lauriello J, et al. An 8-­week, double-­blind, randomized, placebo-­controlled study of olanzapine long-­acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008; 69:790–799.
4. Eli Lily and Company Limited. Summary of Product Characteristics. Zypadhera (olanzapine pamoate monohydrate) 210mg powder and solvent for prolonged release suspension for injection. 2023 (last accessed August 2024); https://www.medicines.org.uk/emc/product/6429/ smpc.
5. Denee TR, et al. Treatment continuation and treatment characteristics of four long acting antipsychotic medications (paliperidone palmitate, risperidone microspheres, olanzapine pamoate and haloperidol decanoate) in the Netherlands. Value Health 2015; 18:A407.
6. Taipale H, et al. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-­a nationwide study with 20-­year follow-­up. Schizophr Bull 2017; 44:1381–1387.
7. O’Neill JR, et al. Implementing gradual, hyperbolic tapering of long-­acting injectable antipsychotics by prolonging the inter-­dose interval: an in silico modelling study. Ther Adv Psychopharmacol 2023; 13:20451253231198463.
8. Citrome L. Long-­acting injectable antipsychotics: what, when, and how. CNS Spectr 2021; 26:118–129.
9. Kochen SA, et al. Olanzapine postinjection delirium/sedation syndrome after long-­acting olanzapine depot injection presenting to the emergency department: practical guidelines for diagnosis and management. Emerg Med J 2024; 41:759–763.
10. McDonnell DP, et al. Post-­injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-­acting injection, II: investigations of mechanism. BMC Psychiatry 2010; 10:45.
11. Podgorná G, et al. Post-­injection delirium/sedation syndrome: a case report and 2-­year follow-­up. Am J Case Rep 2022; 23:e937579.
12. Seebaluck J, et al. Case series profile of olanzapine post-­injection delirium/sedation syndrome. Br J Clin Pharmacol 2023; 89:903–907.
13. Bushes CJ, et al. Olanzapine long-­acting injection: review of first experiences of post-­injection delirium/sedation syndrome in routine clinical practice. BMC Psychiatry 2015; 15:65.
14. Meyers KJ, et al. Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-­acting injection: results from a large observational study. BJPsych Open 2017; 3:186–192.
15. Garg S, et  al. Delayed onset postinjection delirium/sedation syndrome associated with olanzapine pamoate: a case report. J Clin Psychopharmacol 2019; 39:523–524.
16. Eli Lilly Australia Pty Ltd. Consumer Medicine Information: ZYPREXA RELPREVV® (olanzapine pamoate monohydrate). 2024 (last accessed August 2024); https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-­2024-­CMI-­01649-­1&d= 20240807172310101.
17. Pharmaco (N.Z.) Ltd. Consumer Medicine Information: ZYPREXA RELPREVV® (olanzapine pamoate monohydrate). 2023 (last accessed August 2024); https://www.medsafe.govt.nz/consumers/cmi/z/zyprexarelprevvinj.pdf.
18. Siskind D, et al. Monitoring for post-­injection delirium/sedation syndrome with long-­acting olanzapine during the COVID-­19 pandemic. Aust N Z J Psychiatry 2020; 54:759–761.
19. Venkatesan V, et al. Postinjection delirium/sedation syndrome after 31st long-­acting olanzapine depot injection. Clin Neuropharmacol 2019; 42:64–65.
20. Anand E, et al. A 6-­year open-­label study of the efficacy and safety of olanzapine long-­acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation. Neuropsychiatr Dis Treat 2015; 11:1349–1357.
21. Atkins S, et al. A pooled analysis of injection site-­related adverse events in patients with schizophrenia treated with olanzapine long-­acting injection. BMC Psychiatry 2014; 14:7.